Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Farnex Incorporated has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. The busiest examiner is DAVIS, BRIAN J, who is currently responsible for 1 pending office action.
The data shows a balanced distribution where 2 pending office actions are split between 2 distinct examiners. Because there are also 2 distinct art units involved, each application is being reviewed under the specific guidelines of a different technical group. This structure means that the 2 pending office actions are not influencing each other through a shared examiner or art unit.
DAVIS, BRIAN J, as the busiest examiner with 1 pending office action, handles exactly half of the pending portfolio. The involvement of 2 distinct art units within the Biotechnology & Pharmaceuticals sector suggests that Farnex Incorporated is pursuing multiple distinct lines of research. Practitioners must manage the 2 pending office actions by addressing the unique requirements of each art unit and examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| TIEN, LUCY MINYU | 1 | 59.3% | +39.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291160 | NON-LAMELLAR LIQUID CRYSTAL-FORMING COMPOSITION AND USE THEREOF | DAVIS, BRIAN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795805 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | TIEN, LUCY MINYU | 59d overdue |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291160 | NON-LAMELLAR LIQUID CRYSTAL-FORMING COMPOSITION AND USE THEREOF | DAVIS, BRIAN J | 1614 | §103 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 17795805 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | TIEN, LUCY MINYU | 1612 | §103DP | Non-Final OA | 59d overdue | Pending | Jul 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial